

Press Release



The license agreement for Relugolix within the gynecological therapeutic area -Out-licensing to ASKA from Takeda to maximize product value-

TOKYO, May 31st, 2018 – ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo, President: Takashi Yamaguchi, hereinafter "ASKA") and Takeda Pharmaceutical Company Limited (Head Office: Chuo-ku, Osaka, President: Christophe Weber, hereinafter "Takeda") have announced that the two companies have entered into a license agreement regarding Relugolix (generic name, development code: TAK-385) owned by Takeda, which has been out-licensed to ASKA regarding the exclusive marketing rights for uterine fibroids as well as the exclusive developmental and marketing rights for endometriosis in Japan to maximize product value.

Relugolix is being developed as a once-a-day oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the indications of uterine fibroids, endometriosis, and prostate cancer. Takeda has previously held the rights to commercialize Relugolix in Japan*, and in February of this year, filed for a manufacturing and marketing approval application with the Ministry of Health, Labour and Welfare for the treatment of uterine fibroids.

Please note that the current license agreement is only for gynecological disorders, and does not include prostate cancer.

Under this agreement, by out-licensing Relugolix and its exclusive marketing rights for uterine fibroids as well as the exclusive developmental and marketing rights for endometriosis in Japan, Takeda will receive an upfront payment from ASKA as well as royalty payments based on sales performance. The details related to the contract agreement will not be disclosed.

*The rights for Japan and for some other Asian countries are owned by Takeda, while rights in other regions are held by Myovant Sciences Ltd., a biopharmaceutical company established in June 2016 by Takeda and Roivant Sciences Ltd.

[About ASKA Pharmaceutical Co., Ltd.]

Since its establishment in 1920, ASKA Pharmaceutical has been a specialty pharma that focuses on, and provides products related to therapeutic areas in Internal medicine, Obstetrics and gynecology, and Urology, and is expanding its lineup.

For more information, please visit <https://www.aska-pharma.co.jp/english/>

[Inquiries regarding this matter]

Takeda Pharmaceutical Company Limited

TEL: +81-3-3278-2665

ASKA Pharmaceutical Co., Ltd.

TEL: +81-3-5484-8366